Tesamorelin and visceral fat: what the trials show
Tesamorelin is the only peptide whose effect on visceral fat, the deep belly fat, has been measured in large clinical trials. Here's what these trials observed, what they didn't show, and why this finding is of such interest to metabolism research.
Tesamorelin 10 mg – €89.90The complete guide
Visceral fat or subcutaneous fat?
The belly stores two different types of fat:
- subcutaneous fat, just under the skin, the kind you can pinch;
- Visceral fat, which is deeper, surrounds the organs (intestines, liver). It is more hormonally active and, in studies, associated with a higher cardiometabolic risk.
Trials of tesamorelin measure visceral fat using CT scans of the abdomen at the level of the L4-L5 lumbar vertebrae. This is a precise measurement that is independent of weight and waist circumference.
Why does growth hormone affect the belly?
Tesamorelin is a GHRH analogue: it stimulates the pituitary gland, which releases more growth hormone (GH), then the liver produces more IGF-1. GH promotes lipolysis, that is, the release of stored fat, and visceral fat is particularly sensitive to this.
People who accumulate visceral fat often have lower GH secretion. Tesamorelin stimulates this secretion while maintaining its natural rhythms, unlike direct administration of growth hormone.
Clinical trials
| Study | Participants | Main result |
|---|---|---|
| Falutz et al., N Engl J Med 2007 | 412 people living with HIV, excess abdominal fat, 26 weeks | Visceral fat -15.2% versus +5.0% under placebo |
| Falutz et al., J Clin Endocrinol Metab 2010 | Analysis of two phase 3 trials, more than 800 participants | A decrease of approximately 15% has been confirmed; waist circumference and triglycerides are down. |
| Extension phase (52 weeks) | Participants continuing or stopping treatment | The effect is maintained during treatment; visceral fat returns after stopping. |
| Stanley et al., JAMA 2014 | 50 people living with HIV, 6 months | Reduction in liver fat compared to placebo |
In these trials, subcutaneous fat changed little and total weight remained almost stable: tesamorelin primarily alters fat distribution. This is what distinguishes it from molecules studied for weight loss, such as retatrutide.
Liver fat
Visceral fat and liver fat often develop together. Following the trial published in JAMA in 2014, a study published in The Lancet HIV In 2019, Stanley et al. observed a decrease in liver fat and less progression of fibrosis in individuals living with HIV and hepatic steatosis, under tesamorelin treatment. This work explains the current interest in hepatic steatosis (NAFLD/MASLD).
The limitations of these results
- A specific population The large trials focus on people living with HIV and lipodystrophy. The results do not automatically apply to other profiles.
- A reversible effect : visceral fat returns after stopping.
- One point of concern : blood glucose, which growth hormone stimulants can raise (see side effects).
- No authorization in Europe tesamorelin is only available there as a research peptide.
Price
Tesamorelin 10 mg costs €89.90 per lyophilized vial, or €8.99 per milligram. Our batch was analyzed by Janoshik: 98.2% purity and 10.44 mg measured.
10 mg lyophilized vial (€8.99/mg), Janoshik analysis #244206: 98.2% purity, 10.44 mg measured. Shipped from the European Union in 2 to 5 business days; delivery €10, free from €160.
Tesamorelin 10 mg – €89.90Bacteriostatic water 3 ml – €5
- Tesamorelin: the complete guide
- Tesamorelin and bodybuilding
- Side effects and reviews
- Retatrutide or tesamorelin
- Our Janoshik (COA) analysis
Frequently asked questions
Does tesamorelin help you lose belly fat?
In clinical trials, it reduced visceral fat, the deep belly fat, by about 15% over 26 weeks, compared to an increase of about 5% with a placebo. These trials involved people living with HIV and excess abdominal fat.
Does tesamorelin act on subcutaneous fat?
Little change: in the trials, subcutaneous fat changed very little. The effect is mainly on visceral fat, around the organs.
Does tesamorelin help with weight loss?
No, not significantly: total weight remained almost stable in the trials. Tesamorelin primarily changes fat distribution.
What happens when tesamorelin is stopped?
In the extension phase of the trials, visceral fat returned in participants who stopped treatment.
How is visceral fat measured in studies?
By CT scan, on a section of the abdomen at the level of the L4-L5 vertebrae. This measurement distinguishes visceral fat from subcutaneous fat.
Sources: Falutz J. et al., N Engl J Med 2007; Falutz J. et al., J Clin Endocrinol Metab 2010; Stanley T.L. et al., JAMA 2014; Stanley T.L. et al., Lancet HIV 2019; FDA, Egrifta information leaflet. MyPeptide products are intended for scientific laboratory research use only.
